Kinfo
IDEAYA Biosciences Inc. logo

IDEAYA Biosciences Inc.

IDYANASDAQHealthcare·US · USD
$36.11
+0.05 (+0.14%)
Prices as of October 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap3.48B USD
Enterprise value2.70B USD
Trailing P/E-28.21
Forward P/E-9.01
PEG ratio-0.73
Price / sales14.88
Price / book2.90
Profitability
Gross margin0.00%
Operating margin-1380.73%
Profit margin-74.75%
Return on assets-11.54%
Return on equity-16.22%
Income (TTM)
Revenue234.13M USD
Gross profit-139.88M USD
EBITDA-214.20M USD
Net income-175.02M USD
Diluted EPS-$1.94
Rev. growth (YoY)35.02%
Balance sheet
Total cash828.96M USD
Total debt29.31M USD
Debt / equity2.44
Current ratio10.45
Book value / share$12.44
Cash flow (TTM)
Operating cash flow-111.66M USD
Levered free cash flow-70.85M USD
Shares & price
Shares outstanding96.38M
Float90.63M
Held by institutions107.73%
Beta-0.04
50-day MA$38.06
200-day MA$34.14
52-week high$42.68
52-week low$26.20
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-04-1.05-1.22−16.19%2026-05-15-0.53-0.61−15.09%2026-05-05-0.98-1.11−13.27%2026-04-10-0.16-0.14+12.50%
About IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc. is a precision medicine oncology company focused on discovering and developing targeted therapies for cancers defined by specific genetic alterations and biomarker profiles. The company combines small-molecule drug discovery, structural biology, bioinformatics, and translational biomarker expertise to advance investigational medicines designed for molecularly selected patient populations. Its current portfolio spans synthetic lethality, targeted pathway inhibition, and antibody-drug conjugate research across solid tumors, including programs directed at uveal melanoma and other genetically defined cancers. IDEAYA Biosciences Inc. works with a research-driven model that integrates internal discovery capabilities with clinical development and collaboration-based programs, making it a notable participant in the broader oncology innovation landscape. Headquartered in South San Francisco, California, the company is positioned around precision oncology approaches intended to match treatments to the biological drivers of disease.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yujiro S. Hata
Employees
131
Headquarters
South San Francisco, CA, United States

Frequently asked questions about IDEAYA Biosciences Inc.